



California State Board of Pharmacy
2720 Gateway Oaks Drive, Suite 100
Sacramento, CA 95833
Phone: (916) 518-3100 Fax: (916) 574-8618
www.pharmacy.ca.gov

Business, Consumer Services and Housing Agency
Department of Consumer Affairs
Gavin Newsom, Governor



Notice of Board Meeting

Dates & Times: June 19, 2025, 1:00 p.m.
June 20, 2025, 9:00 a.m.

The California State Board of Pharmacy (Board) will meet by teleconference in accordance with Government Code section 11123.2 at the above-noted dates and times, with the following physical location available for members of the Board and the public to physically attend and participate in the meeting:

1625 N. Market Blvd.
Hearing Room, First Floor
Sacramento, CA 95834

MEMBERS OF THE PUBLIC MAY PARTICIPATE FROM A REMOTE LOCATION BY JOINING THE MEETING VIA WEBEX:

WebEx for June 19, 2025:

[Click here to join the meeting](#)

If joining using the link above

Webinar number: 2490 991 8487

Webinar password: CSBP619

If joining by phone

+1-415-655-0001 US Toll

Access code: 2490 991 8487

Passcode: 2727619

WebEx for June 20, 2025:

[Click here to join the meeting](#)

If joining using the link above

Webinar number: 2491 546 3279

Webinar password: CSBP620

If joining by phone

+1-415-655-0001 US Toll

Access code: 2491 546 3279

Passcode: 2727620

Members of the public may but are not required to identify themselves. When signing into the WebEx platform, participants may be asked for their name and email address.

Participants who choose not to provide their names will need to provide a unique identifier such as their initials or another alternative, so that the meeting moderator can identify individuals who wish to make public comment. Participants who choose not to provide their email address may use a fictitious email address in the following sample format: XXXXX@mailinator.com.

Members of the public may also view a livestream of the meeting at <https://thedcapage.blog/webcasts>. Using the livestream link will allow only for observation with closed captioning. Livestream availability cannot be guaranteed due to resource limitations or technical difficulties. The meeting will not be cancelled if livestream becomes unavailable.

IMPORTANT NOTICES TO THE PUBLIC:

The time and order of agenda items are subject to change at the discretion of the Board president. If a quorum of the Board becomes unavailable, the president may, at their discretion, continue to discuss items from the agenda to make recommendations to the full Board at a future meeting (Government Code section 11125(c)).

The meeting is open to the public except when specifically noticed otherwise, in accordance with the Open Meeting Act.

The meeting is accessible to the physically disabled. To request disability-related accommodations, use the contact information below. Please submit your request at least five (5) business days before the meeting to help ensure availability of the requested accommodation.

Contact Person: Debbie Damoth
(916) 518-3090 or Debbie.Damoth@dca.ca.gov
Board of Pharmacy
2720 Gateway Oaks Drive, Suite 100
Sacramento CA 95833

The Board welcomes and encourages public participation at its meetings. The public may take appropriate opportunities to comment on any issue before the Board at the time the item is heard. If public comment is not specifically requested, members of the public should feel free to request an opportunity to comment.

Note: Pharmacists and pharmacy technicians who attend the full day of the Board meeting on June 20, 2025, in person, may be awarded up to 6 hours of CE, in accordance with the Board's CE regulations. Sign-in and sign-out on the day of the meeting will be required for CE credit.

Pharmacists and pharmacy technicians who attend the meeting on June 20, 2025, virtually may receive 6 hours of CE, in accordance with the Board's CE regulations. To earn the CE for attending virtually, individuals must attend the meeting online via PharmEd. Use the link below to register.

Agenda

Discussion and action may be taken on any agenda item.

June 19, 2025

Call to Order

1:00 p.m.

- I. Call to Order, Establishment of Quorum, and General Announcements (Including Possible Notifications, Actions, and Disclosures Pursuant to Government Code section 11123.2(j))**
- II. Public Comments on Items Not on the Agenda/Agenda Items for Future Meetings**
Note: The Board may not discuss or take action on any matter raised during this public comment section that is not included on this agenda, except to decide whether to place the matter on the agenda of a future meeting. [Government Code sections 11125, 11125.7(a)]
- III. Recognition and Celebration of Pharmacists Licensed in California for 40 Years**
- IV. Approval of Board Meeting Minutes**
 - a. April 9-10, 2025 Board Meeting
 - b. May 21, 2025 Disciplinary Petition Committee Meeting
- V. Report by the California Department of Consumer Affairs**
- VI. Discussion and Consideration of the Board's Strategic Plan**
- VII. Discussion and Possible Action Regarding Executive Officer Exempt Level Change and Salary Increase**
- VIII. Closed Session Matters**
 - a. Pursuant to Government Code section 11126(c)(3), the Board will Convene in Closed Session to Deliberate on Disciplinary Matters, Including Proposed Decisions, Stipulated Settlements, Default Decisions, Petitions for Reinstatement or Modification of Penalty, and Any Other Disciplinary Matters
 - b. Pursuant to Government Code section 11126(c)(1), the Board will Convene in Closed Session to Consider the Preparation, Approval, Grading, or Administration of One or More Licensing Examination(s)
 - c. Pursuant to Government Code section 11126(e)(1), the Board will Convene in Closed Session to Confer with its Legal Counsel Regarding Pending Litigation
 1. *Yana Budnitsky v. California State Board of Pharmacy, Los Angeles County Superior Court Case 24STCP01797*

IX. Reconvene in Open Session to Adjourn for the Day

Adjournment will immediately follow closed session, and there will be no other items of business discussed. Adjournment for the day may not be viewable on livestream.

June 20, 2025

9:00 a.m.

X. Discussion and Possible Action Related to Proposed Regulations, Title 16, California Code of Regulations, Repeal of Sections 1708.3, 1708.4, 1708.5, 1735 et seq., and 1751 et seq. and Addition of Sections 1735 et seq., 1736 et seq., 1737 et seq., and 1738 et seq. Related to Compounded Drug Preparations, Hazardous Drugs, and Radiopharmaceuticals in Response to Comments from the Office of Administrative Law, if Any Received

XI. Discussion and Possible Action Related to Proposed Amendment to California Code of Regulations, Title 16, Section 1713 Related to Automated Patient Delivery Systems (APDS) Consultation

XII. Discussion and Possible Action Related to Proposed Amendment to California Code of Regulations, Title 16, Section 1711 Related to Quality Assurance Programs, Including Review of Comments Received During the Second 15-Day Comment Period

XIII. Communication and Public Education Committee Report

- a. Education Materials on Buprenorphine
- b. Update on Communication and Public Education Activities by Staff
 1. The Script
 2. Staff Outreach
 3. News Media Inquiries

XIV. Enforcement and Compounding Committee Report

- a. Summary of Presentation on Board's Inspection Program
- b. Summary of Presentation on Board's Citation Program
- c. Summary of Presentation on Quality Assurance Reports Received Pursuant to California Code of Regulations, Title 16, Section 1711(f) Related to the Use of Automated Drug Delivery Systems
- d. Discussion and Consideration of Updates to Frequently Asked Questions Related to the Board's Ask An Inspector Program
- e. Discussion and Consideration of Updates to Frequently Asked Questions Related to Assembly Bill 1286 (Haney, Chapter 470, Statutes of 2023)
- f. Discussion, Consideration, and Possible Action on Proposal to Add New Section 1707.51 Related to Accessible Prescription Drug Labels to Article 2 of Division 17 of Title 16 of the California Code of Regulations
- g. Discussion and Consideration of Enforcement Statistics

XV. Legislation and Regulation Committee Report

- a. Discussion and Consideration of Pending Legislation Impacting the Practice of Pharmacy, the Board's Jurisdiction, or Board Operations
 - 1. Assembly Bill 50 (Bonta, 2025) Pharmacists: Furnishing Contraceptives
 - 2. Assembly Bill 309 (Zbur, 2025) Hypodermic Needles and Syringes
 - 3. Assembly Bill 447 (González, 2025) Emergency Room Patient Prescriptions: Dispensing Unused Portions Upon Discharge
 - 4. Assembly Bill 529 (Ahrens, 2025) Pharmacy: Declared State of Emergency
 - 5. Assembly Bill 669 (Haney, 2025) Substance Use Disorder Coverage
 - 6. Assembly Bill 957 (Ortega, 2025) Cigarette and Tobacco Products: Retail Sale: Pharmacies
 - 7. Assembly Bill 968 (Boerner, 2025) Pharmacists: Self-Administered FDA-approved Nonhormonal Contraceptives
 - 8. Assembly Bill 1460 (Rogers, 2025) Prescription Drug Pricing
 - 9. Assembly Bill 1503 (Berman, 2025) Pharmacy
 - 10. Senate Bill 40 (Wiener, 2025) Health Care Coverage: Insulin
 - 11. Senate Bill 41 (Wiener, 2025) Pharmacy Benefits
 - 12. Senate Bill 306 (Becker, 2025) Health Care Coverage: Prior Authorizations
 - 13. Senate Bill 470 (Laird, 2025) Bagley-Keene Open Meeting Act: Teleconferencing
 - 14. Senate Bill 497 (Wiener, 2025) Legally Protected Health Care Activity
 - 15. Senate Bill 641 (Ashby, 2025) Department of Consumer Affairs and Department of Real Estate: States of Emergency: Waivers and Exemptions
- b. Discussion and Consideration of Board Regulations
 - 1. Board-Adopted Regulations Approved by the Office of Administrative Law
 - i. Proposed Regulation to Add Title 16, California Code of Regulations, Section 1700 Related to Digital Signatures
 - 2. Board-Adopted Regulations - Board Staff Drafting Final Rulemaking Documents
 - i. Proposed Regulation to Add Title 16, California Code of Regulations, Section 1708.2 Related to Discontinuance of Business
 - 3. Board-Approved Regulations Undergoing Pre-Notice Review by the Department of Consumer Affairs, or Business, Consumer Services and Housing Agency
 - i. Proposed Regulation to Add Title 16, California Code of Regulations, Section 1746.6 Related to Medication Assisted Treatment Protocol
 - ii. Proposed Regulation to Amend Title 16, California Code of Regulations, Section 1707.4 Related to Central Fill Pharmacies
 - 4. Board-Approved Regulations – Board Staff Drafting Initial Rulemaking Documents
 - i. Proposed Regulation to Amend Title 16, California Code of Regulations, Section 1715.1 Related to Automated Drug Delivery Systems Self-Assessment
 - ii. Proposed Regulation to Add Title 16, California Code of Regulations, Sections 1750 and 1750.1 Related to Outsourcing Facilities

XVI. Licensing Committee Report

- a. Discussion and Consideration of Title 16, California Code of Regulations, Section

1793.8 Related to Technicians in Hospitals with Clinical Pharmacy Programs, Including Summary of Presentations Received

- b. Discussion and Consideration of Pharmacist to Pharmacy Technician Ratio in the Inpatient Setting
- c. Discussion and Consideration of Proposed Changes to Application Questions for Individual Licenses
- d. Summary of Presentation, Discussion, and Consideration of Results of Pharmacist and Pharmacy Technician Workforce Surveys
- e. Discussion and Consideration of Licensing Statistics

XVII. Organizational Development Committee Report

- a. Budget Report
- b. Board Member Attendance and Mail Vote Information
- c. Personnel Update
- d. Future Meeting Dates

XVIII. Executive Officer Report

XIX. Closed Session Matters

- a. Pursuant to Government Code section 11126(c)(3), the Board will Convene in Closed Session to Deliberate on Disciplinary Matters, Including Proposed Decisions, Stipulated Settlements, Default Decisions, Petitions for Reinstatement or Modification of Penalty, and Any Other Disciplinary Matters
- b. Pursuant to Government Code section 11126(c)(1), the Board will Convene in Closed Session to Consider the Preparation, Approval, Grading, or Administration of One or More Licensing Examination(s)
- c. Pursuant to Government Code section 11126(e)(1), the Board will Convene in Closed Session to Confer with its Legal Counsel Regarding Pending Litigation
 - 1. *Yana Budnitsky v. California State Board of Pharmacy, Los Angeles County Superior Court Case 24STCP01797*
 - 2. *Coastal Drugs, LLC v. California State Board of Pharmacy, Sacramento County, Superior Court Case 24WM000140*

XX. Reconvene in Open Session to Adjourn the Meeting

Adjournment will immediately follow closed session, and there will be no other items of business discussed. Meeting adjournment may not be viewable on livestream.

XXI. Adjournment

Upon conclusion of business